Free Trial
ETR:MDG1

Medigene (MDG1) Stock Price, News & Analysis

€1.93
+0.05 (+2.67%)
(As of 10/21/2024 ET)

About Medigene Stock (ETR:MDG1)

Key Stats

Today's Range
€1.87
€1.93
50-Day Range
€1.02
€2.32
52-Week Range
€1.60
€5.51
Volume
913 shs
Average Volume
306,207 shs
Market Capitalization
$28.39 million
P/E Ratio
N/A
Dividend Yield
1.31%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

Receive MDG1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter.

MDG1 Stock News Headlines

Unveiled: NVIDIA’s "Secret Royalty" Program
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?
Medigene will Present at ASGCT 2024 and Host R&D Event
See More Headlines

MDG1 Stock Analysis - Frequently Asked Questions

Medigene's stock was trading at €1.53 at the start of the year. Since then, MDG1 stock has increased by 26.3% and is now trading at €1.93.
View the best growth stocks for 2024 here
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medigene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX) and Ampio Pharmaceuticals (AMPE).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
76
Year Founded
N/A

Profitability

Net Income
$-15,930,000.00
Net Margins
-213.98%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.45 million
Cash Flow
€1.41 per share
Book Value
€1.33 per share

Miscellaneous

Free Float
N/A
Market Cap
$28.39 million
Optionable
Not Optionable
Beta
0.84
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (ETR:MDG1) was last updated on 10/22/2024 by MarketBeat.com Staff
From Our Partners